Biogen Inc. expects to incur approximately $164 million in pre-tax acquired in-process research and development, upfront and milestone expenses for the second quarter of 2026, impacting net income per diluted share by approximately $0.95. The company also anticipates an estimated charge for the third quarter of 2026 ranging from $290 million to $320 million, which is expected to impact net income per diluted share by $1.75 to $1.95. Biogen is a biotechnology company that develops and manufactures products for neurological and related diseases.
